endpts.com·Apr 27, 2026
Fathom Therapeutics, formerly known as Atommap, has raised $47 million in a Series A funding round to enhance its drug discovery efforts by integrating artificial intelligence and physics. The company aims to leverage advanced computational techniques in its research initiatives.
Fathom Therapeutics' successful $47M Series A funding round emphasizes the growing investor confidence in companies that integrate AI with traditional scientific approaches, such as physics, to enhance drug discovery processes. For professionals in healthtech and biotech, this serves as a key indicator of the strategic importance of cross-disciplinary innovations and could inspire investment or collaboration opportunities within AI-driven biotech ventures.